Dan Tran, MD
Ophthalmology · Long Beach, CANPI 1487767190
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $165,188 of the $231,993 with a category attached, or 71.2%. 38 manufacturers reported payments, led by Rxsight Inc at 49.7% of the total. Reporting peaked in 2022 at $118,233 and has fallen 80.2% since, to $23,419 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 877 payments — averaging $264.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$115K
- Lensar, Inc.$34K
- Alcon Research LLC$21K
- Glaukos Corporation$16K
- Alcon$11K
- Beaver-visitec International, Inc.$10K
- plus $24K from 32 others
Across 96 payments — averaging $5775.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$266K
- Glaukos Corporation$133K
- Rxsight Inc$60K
- Beaver-visitec International, Inc.$46K
- Johnson & Johnson Surgical Vision, Inc.$31K
- Ivantis, Inc$15K
- plus $3K from 1 others
What the payments were for
- Consulting fees$165,18871%
- Speaking & faculty fees$20,5029%
- Travel & lodging$5,4882%
- Food & beverage$33,10314%
- Education$600%
- Gifts$1310%
- Entertainment$460%
- Other$7,4753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$104,506
- LENSAR LASER SYSTEM$33,580
- RXSIGHT CONTACT LENS$10,250
- RXSIGHT INJECTOR CARTRIDGE$10,250
- RXSIGHT INJECTOR HANDPIECE$10,250
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$10,250
- LIGHT ADJUSTABLE LENS (LAL)$8,050
- LenSx$5,984
- iDoseTR$5,755
- Hydrus$5,500
- KXL System$5,390
- Centurion$2,940
- ILUX$2,450
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$2,200
- NGENUITY$2,170
- DURYSTA$2,124
- CE-marked KXLA system$800
- AcrySof IQ PanOptix$754
- VisuMax$682
- Wavelight Refractive Suite$673
How this compares
$231,993 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 122 | $124,186 |
| RestasisCyclosporine | 108 | $101,293 |
| XiidraLifitegrast | 97 | $98,567 |
| LumiganBimatoprost | 124 | $59,909 |
| Cyclosporine | 115 | $40,898 |
| Bromfenac Sodium | 326 | $35,167 |
| ProlensaBromfenac Sodium | 95 | $32,476 |
| Lotemax SmLoteprednol Etabonate | 95 | $26,290 |
| VevyeCyclosporine | 29 | $24,808 |
| Prednisolone Acetate | 736 | $22,300 |
| CequaCyclosporine | 25 | $20,635 |
| MoxifloxacinMoxifloxacin Hcl | 772 | $16,329 |
| IlevroNepafenac | 37 | $14,118 |
| Alphagan PBrimonidine Tartrate | 35 | $13,548 |
| TyrvayaVarenicline Tartrate | 15 | $13,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $1,572 | $234,873255 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $5,145 | $181,706290 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate, Alrex, Besivance | $614 | $83,071303 claims |
| Harrow Eye, LLCVevye | $166 | $24,80829 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $831 | $20,63525 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $900 | $19,07247 claims |
| NovartisIlevro | $112 | $14,11837 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $402 | $13,07715 claims |
| AlconSimbrinza | $11,473 | $8,81639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.